Several members and affiliates of the LaMontagne Center have been publishing research related to COVID-19.

LCID Member Papers
In scientific journals, preprints, etc.

• Goike J, Hsieh CL, Horton AP, Gardner EC, Zhou L, Bartzoka F, Wang N, Javanmardi K, Herbert A, Abbassi S, Xie X, Xia H, Shi PY, Renberg R, Segall- Shapiro TH, Terrace CI, Wu W, Shroff R, Byrom M, Ellington AD, Marcotte EM, Musser JM, Kuchipudi SV, Kapur V, Georgiou G, Weaver SC, Dye JM, Boutz DR, McLellan JS, Gollihar JD. SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode. Commun Biol. 2023 Dec 11;6(1):1250. PMID: 38082099; PMCID: PMC10713552.

• Weber T, Dähling S, Rose S, Affeldt P, Vanshylla K, Ullrich L, Gieselmann L, Teipel F, Gruell H, Di Cristanziano V, Kim DS, Georgiou G, Koch M, Kreer C, Klein F. Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool. Sci Immunol. 2023 Nov 17;8(89):eadk5845. Epub 2023 Nov 17. PMID: 37976348.

• Hutchinson GB, Abiona OM, Ziwawo CT, Werner AP, Ellis D, Tsybovsky Y, Leist SR, Palandjian C, West A, Fritch EJ, Wang N, Wrapp D, Boyoglu-Barnum S, Ueda G, Baker D, Kanekiyo M, McLellan JS, Baric RS, King NP, Graham BS, Corbett-Helaire KS. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera. Nat Commun. 2023 Oct 4;14(1):6195. PMID: 37794071; PMCID: PMC10551005.

• Tse LV, Hou YJ, McFadden E, Lee RE, Scobey TD, Leist SR, Martinez DR, Meganck RM, Schäfer A, Yount BL, Mascenik T, Powers JM, Randell SH, Zhang Y, Wang L, Mascola J, McLellan JS, Baric RS. A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus. Sci Transl Med. 2023 Sep 27;15(715):eadg5567. Epub 2023 Sep 27. PMID: 37756379.

• Kumar N, Towers D, Myers S, Galvin C, Kireev D, Ellington AD, Akinwande D. Graphene Field Effect Biosensor for Concurrent and Specific Detection of SARS- CoV-2 and Influenza. ACS Nano. 2023 Sep 26;17(18):18629-18640. Epub 2023 Sep 13. PMID: 37703454.

• McNamara RP, Maron JS, Boucau J, Roy V, Webb NE, Bertera HL, Barczak AK, Positives Study Staff T, Franko N, Logue JK, Kemp M, Li JZ, Zhou L, Hsieh CL, McLellan JS, Siedner MJ, Seaman MS, Lemieux JE, Chu HY, Alter G. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern. mBio. 2023 Aug 3:e0090223. Epub ahead of print. PMID: 37535402.

• Silva RP, Huang Y, Nguyen AW, Hsieh CL, Olaluwoye OS, Kaoud TS, Wilen RE, Qerqez AN, Park JG, Khalil AM, Azouz LR, Le KC, Bohanon AL, DiVenere AM, Liu Y, Lee AG, Amengor DA, Shoemaker SR, Costello SM, Padlan EA, Marqusee S, Martinez- Sobrido L, Dalby KN, D'Arcy S, McLellan JS, Maynard JA. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. Elife. 2023 Mar 21;12:e83710. PMID: 36942851; PMCID: PMC10030117.

• Qerqez AN, Silva RP, Maynard JA. Outsmarting Pathogens with Antibody Engineering. Annu Rev Chem Biomol Eng. 2023 Mar 14. Epub ahead of print. PMID: 36917814.

• Bowen JE, Park YJ, Stewart C, Brown JT, Sharkey WK, Walls AC, Joshi A, Sprouse KR, McCallum M, Tortorici MA, Franko NM, Logue JK, Mazzitelli IG, Nguyen AW, Silva RP, Huang Y, Low JS, Jerak J, Tiles SW, Ahmed K, Shariq A, Dan JM, Zhang Z, Weiskopf D, Sette A, Snell G, Posavad CM, Iqbal NT, Geffner J, Bandera A, Gori A, Sallusto F, Maynard JA, Crotty S, Van Voorhis WC, Simmerling C, Grifantini R, Chu HY, Corti D, Veesler D. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Sci Immunol. 2022 Nov 10:eadf1421. Epub ahead of print. PMID: 36356052.

• McColl ER, Croyle MA, Zamboni WC, Honer WG, Heise M, Piquette-Miller M, Goralski KB. COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics. Drug Metab Dispos. 2022 Oct 23:DMD-AR-2022-000934. doi: 10.1124/dmd.122.000934. Epub ahead of print. PMID: 36273826.

• Chang MR, Tomasovic L, Kuzmina NA, Ronk AJ, Byrne PO, Johnson R, Storm N, Olmedillas E, Hou YJ, Schäfer A, Leist SR, Tse LV, Ke H, Coherd C, Nguyen K, Kamkaew M, Honko A, Zhu Q, Alter G, Saphire EO, McLellan JS, Griffiths A, Baric RS, Bukreyev A, Marasco WA. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Nat Commun. 2022 Oct 3;13(1):5814. PMID: 36192374; PMCID: PMC9528872.

• Bazzi SA, Maguire C, Holay N, Geltman J, Hurley K, DiPasquale C, Abigania M, Olson E, Ehrlich LIR, Triplett TA, Melamed E. Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy. Mult Scler Relat Disord. 2022 Sep 26;68:104195. Epub ahead of print. PMID: 36223705; PMCID: PMC9511881.

• Javanmardi K, Segall-Shapiro TH, Chou CW, Boutz DR, Olsen RJ, Xie X, Xia H, Shi PY, Johnson CD, Annapareddy A, Weaver S, Musser JM, Ellington AD, Finkelstein IJ, Gollihar JD. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. Cell Host Microbe. 2022 Sep 14;30(9):1242-1254.e6. Epub 2022 Aug 4. PMID: 35988543; PMCID: PMC9350683.

• Ozonoff A, Schaenman J, Jayavelu ND, Milliren CE, Calfee CS, Cairns CB, Kraft M, Baden LR, Shaw AC, Krammer F, van Bakel H, Esserman DA, Liu S, Sesma AF, Simon V, Hafler DA, Montgomery RR, Kleinstein SH, Levy O, Bime C, Haddad EK, Erle DJ, Pulendran B, Nadeau KC, Davis MM, Hough CL, Messer WB, Higuita NIA, Metcalf JP, Atkinson MA, Brakenridge SC, Corry D, Kheradmand F, Ehrlich LIR, Melamed E, McComsey GA, Sekaly R, Diray-Arce J, Peters B, Augustine AD, Reed EF, Altman MC, Becker PM, Rouphael N; IMPACC study group members. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study. EBioMedicine. 2022 Sep;83:104208.  Epub 2022 Aug 8. PMID: 35952496; PMCID: PMC9359694.

• MV Gadush, GA Sautto, H Chandrasekaran, A Bensussan, TM Ross, GC Ippolito, MD Person. Template-Assisted De Novo Sequencing of SARS-CoV-2 and Influenza Monoclonal Antibodies by Mass Spectrometry. J Proteome Res. June 2, 2022. 

• CL Hsieh, JS McLellan. Protein engineering responses to the COVID-19 pandemic. Current Opinion in Structural Biology, 102385. June 2022 edition.

• AD Dang, TD Vu, HH Vu, AT Van Pham, MTN Dang, B Van Le, TH Duong, ... JS McLellan, ... Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1 …Vaccine. May 14, 2022. (In press, corrected proof).

• EE Escobar, S Wang, R Goswami, MB Lanzillotti, L Li, JS McLellan, ... Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry. Analytical Chemistry. April 7, 2022.

• AR Shiakolas, KJ Kramer, NV Johnson, SC Wall, N Suryadevara, ... JS McLellan... Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nature Biotechnology, 1-6. March 3, 2022.

• SM Costello, SR Shoemaker, HT Hobbs, AW Nguyen, CL Hsieh, ... JS McLellan. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nature Structural & Molecular Biology 29 (3), 229-238. March 2, 2022.

• P Pitisuttithum, V Luvira, S Lawpoolsri, S Muangnoicharoen, JA Maynard, JS McLellan, JE Pak, S Marqusee. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase … EClinicalMedicine 45, 101323. March 1, 2022.

• SR Shoemaker, SM Costello, HT Hobbs, AW Nguyen, CL Hsieh, JA Maynard, JS McLellan, JE Pak, S Marqusee. The SARS-CoV-2 spike protein reversibly samples an open-trimer conformation exposing novel epitopes. Biophysical Journal 121 (3), 29a. February 22, 2022

• N Li, B Zhao, R Stavins, A Sol Peinetti, N Chauhan, R Bashir, BT Cunningham, WP King, Y Lu, E Valera, X Wang. Overcoming the limitations of COVID-19 diagnostics with nanostructures, nucleic acid engineering, and additive manufacturing. Cur. Opin. Solid State & Material Science, 26, 100966. February 2022.

• H Chawla, SE Jossi, SE Faustini, F Samsudin, JD Allen, Y Watanabe, ML Newby, E Marcial-Juárez, RE Lamerton, JS McLellan, PJ Bond, AG Richter, AF Cunningham, M Crispin. Glycosylation and serological reactivity of an expression-enhanced SARS-CoV-2 viral spike mimetic. Journal of molecular biology 434 (2), 167332. January 30, 2022.

• K Javanmardi, TH Segall-Shapiro, CW Chou, DR Boutz, RJ Olsen, X Xie, ... AD Ellington. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. bioRxiv. January 1, 2022.

• N Li, B Zhao, R Stavins, AS Peinetti, N Chauhan, R Bashir, BT Cunningham, WP King, Y Lu, E Valera, X Wang. Overcoming the limitations of COVID-19 diagnostics with nanostructures, nucleic acid engineering, and additive manufacturing​​​​​​​. Cur. Opin. Solid State & Material Science, 26, 100966. 2021.

• JJ Lavinder, GC Ippolito. Boosted immunity to the common cold might protect children from COVID-19. Nat Immunol. December 21, 2021.

• C-L Hsieh, AP Werner, SR Leist, et al with BS Graham, KS Corbett, JS McLellan. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports. November 2, 2021.

• CD Swaim, Y-C Perng, X Zhao, LA Canadeo, HH Harastani, TL Darling, ACM Boon, DJ Lenschow, and JM Huibregtse.  6-Thioguanine Blocks SARS-CoV-2 Replication by Inhibition of PLpro. iScience. Volume 24, Issue 10, October 22, 2021.

• P Kaplonek, C Wang, Y Bartsch, S Fischinger, MJ Gorman, K Bowman, J Kang, D Dayal, P Martin, RP Nowak, A-C Villani, C-L Hsieh, NC Charland, ALK Gonye, I Gushterova, HK Khanna, TJ LaSalle, KM Lavin-Parsons, BM Lilley, CL Lodenstein, K Manakongtreecheep, JD Margolin, BN McKaig, M Rojas-Lopez, BC Russo, N Sharma, J Tantivit, MF Thomas, M Sade-Feldman, J Feldman, B Julg, EJ Nilles, ER Musk, AS Menon, ES Fischer, JS McLellan, A Schmidt, MB Goldberg, MR Filbin, N Hacohen, DA Lauffenburger, G Alter. Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology 6 (64), eabj2901. October 15, 2021.

• JM Schaub, C-W Chou, H-C Kuo, K Javanmardi, C-L Hsieh,  JA Goldsmith, AM DiVenere, KC Le, D Wrapp, PO Byrne, CK Hjorth, NV Johnson, J Ludes-Meyers, AW Nguyen, N Wang, JJ Lavinder, GC Ippolito, JA Maynard, JS McLellan, IJ Finkelstein. Expression and characterization of SARS-CoV-2 spike protein. Nature Protocols. October 5, 2021.

• KJ Kramer, NV Johnson, AR Shiakolas, et al with  JE Crowe Jr, A Bukreyev, RH Carnahan, JS McLellan, IS Georgiev. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports. October 5, 2021.

• D Haslwanter, ME Dieterle, AZ Wec, CM O’Brien, M Sakharka, C Florez, K Tong, CG Rappazzo, G Lasso, O Vergnolle, AS Wirchnianski, RH Bortz II, E Laudermilch, JM Fels, A Mengotto, RJ Malonis, GI Georgiev, JA Quiroz, D Wrapp, N Wang, KE Dye, J Barnhill, JM Dye, JS McLellan, JP Daily, JR Lai, AS Herbert, LM Walker, K Chandran, and RK Jangra. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. mBio. October 5, 2021.

• AS Peinetti, RJ Lake, W Cong, L Cooper, Y Wu, Yu Ma, GT Pawel, ME Toimil-Molares, C Trautmann, L Rong, B Mariñas, O Azzaroni, and Y Lu. Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors. Sci. Adv. 7, eabh2848. September 22, 2021.

• E Andreano, G Piccini, D Licastro, L Casalino, NV Johnson, I Paciello, S Dal Monego, E Pantano, N Manganaro, A Manenti, R Manna, E Casa, I Hyseni, L Benincasa, E Montomoli, RE Amaro, JS McLellan, and R Rappuoli. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. PNAS. 118 (36) e2103154118. September 7, 2021.

• J Goldsmith, AM DiVenere, JA Maynard, JS McLellan. Structural basis for antibody binding to adenylate cyclase toxin reveals RTX-linkers as key neutralization-sensitive epitopes. Plos Pathogens 17(9): e1009920. September 21, 2021.

• MPACC Manuscript Writing Team; IMPACC Network Steering Committee. N Rouphael, H Maecker, RR Montgomery, J Diray-Arce, SH Kleinstein, MC Altman, SE Bosinger, W Eckalbar, L Guan, CL Hough, F Krammer, C Langelier, O Levy, K McEnaney, B Peters, A Rahman, JV Rajan, S Sigelman, H Steen, H van Bakel, A Ward, MR Wilson, P Woodruff, CR Zamecnik, AD Augustine, A Ozonoff, EF Reed, PM Becker, N Agudelo Higuita, MC Altman, MA Atkinson, LR Baden, PM Becker, C Bime, SC Brakenridge, CS Calfee, CB Cairns, D Corry, MM Davis, AD Augustine, LIR Ehrlich, EK Haddad, DJ Erle, A Fernandez-Sesma, DA Hafler, CL Hough, F Kheradmand, SH Kleinstein, M Kraft, O Levy, GA McComsey, E Melamed, W Messer, J Metcalf, RR Montgomery, KC Nadeau, A Ozonoff, B Peters, B Pulendran, EF Reed, N Rouphael, M Sarwal, J Schaenman, R Sekaly, AC Shaw, V Simon. (2021). Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. Sci Immunol. 6(62). PubMed PMID: 34376480. August 10, 2021.

• SM Costello, SR Shoemaker, HT Hobbs, AW Nguyen, C-L Hsieh, JA Maynard, JS McLellan, JE Pak, S Marqusee. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. bioRxiv 2021.07.11.451855; (Preprint). July 11, 2021.

• X Wang, Z Du, KE Johnson, RF Pasco, SJ Fox, M Lachmann, JS McLellan, and LA Meyers. Effects of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, United States. Emerging Infectious Diseases. Volume 27, Number 7—July 2021.

• MD Hall, JM Anderson, A Anderson, D Baker, J Bradner, KR Brimacombe, EA Campbell, KS Corbett, K Carter, S Cherry, L Chiang, T Cihlar, E De Wit, M Denison, M Disney, CV Fletcher, SL Ford-Scheimer, M Götte, AC Grossman, FG Hayden, DJ Hazuda, CA Lanteri, H Marston, AD Mesecar, S Moore, JO Nwankwo, J O’Rear, G Painter, K Singh Saikatendu, CA Schiffer, TP Sheahan, P-Y Shi, HD Smyth, MJ Sofia, M Weetall, SK Weller, R Whitley, AS Fauci, CP Austin, FS Collins, AJ Conley, MI Davis. Report of the national institutes of health SARS-CoV-2 antiviral therapeutics summit. The Journal of infectious diseases 224 (Supplement_1), S1-S2192021. June 10, 2021

• WN Voss, YJ Hou, NV Johnson, G Delidakis, JE Kim , K Javanmardi, AP Horton, F Bartzoka, CJ Paresi, Y Tanno, C-W Chou, SA Abbasi, W Pickens, K George, DR Boutz, DM Towers, JR McDaniel, D Billick, J Goike, L Rowe, D Batra, J Pohl, J Lee, S Gangappa, S Sambhara, M Gadush, N Wang, MD Person, BL Iverson, JD Gollihar, J Dye , A Herbert, IJ Finkelstein, RS Baric, JS McLellan, G Georgiou, JJ Lavinder, GC Ippolito. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science. 372(6546):1108-1112. PMID: 33947773. June 4, 2021.

• AR Shiakolas, KJ Kramer, Dl Wrapp, SI Richardson, A Schäfer, S Wall, N Wang, K Janowska, KA Pilewski, R Venkat, R Parks, NP Manamela, N Raju, E Friedman Fechter, CM Holt, N Suryadevara, RE Chen, DR Martinez, RS Nargi, RE Sutton, JE Ledgerwood, BS Graham, MS Diamond, BF Haynes, P Acharya, RH Carnahan, JE Crowe Jr, RS Baric, L Morris, JS McLellan, IS Georgie. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine 2 (6), 100313. June 2021.

• T Li, W Xue, Q Zheng, S Song, C Yang, HL Xiong, S Zhang, M Hong, YL Zhang, H Yu, Y Zhang, H Sun, Y Huang, T Deng, X Chi, J Li, S Wang, L Zhou, T Chen, Y Wang, T Cheng, T-Y Zhang, Q Yuan, Q Zhao, J Zhang, J McLellan, Z Hong Zhou, Z Zhang, Y Gu, S Li, N Xia. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist to circulating variants. Research Square (Preprint). June 2021.

• PS Arunachalam, AC Walls, N Golden, C Atyeo, S Fischinger, C Li, P Aye, ... McLellan, JS, ... Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 594 (7862), 253-258. June 2021.

• S Bhadra, TE Riedel, S Lakhotia, ND Tran, AD Ellington. High-surety isothermal amplification and detection of SARS-CoV-2. Msphere 6 (3), e00911-2072021. May 19, 2021.

• BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... McLellan, JS, ... The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science translational medicine 13 (593). May 12, 2021.

• M Sakharkar, CG Rappazzo, WF Wieland-Alter, CL Hsieh, D Wrapp, ... JS McLellan, ... Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science immunology 6 (56). February 23, 2021.

• TE Sztain, S-H Ahn, et. al with JS McLellan. A glycan gate controls opening of the SARS-CoV-2 spike protein. bioRxiv 2021.02.15.431212. February 15, 2021.

• AD Brunaugh, H Seo, Z Warnken, L Ding, SH Seo, HDC Smyth. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae PloS one 16 (2), e0246803132021. February 11, 2021.

• Y Huang, AW Nguyen, C-L Hsieh,  R Silva, OS Olaluwoye, RE Wilen, TS Kaoud, LR Azouz, AN Qerqez, KC Le, AL Bohanon,AM DiVenere, Y Liu, AG Lee, D Amengor, KN Dalby, y S D’Arc, JS McLellan, JA Maynard. Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses. bioRxiv 2021.01.31.428824. (Preprint). Commentary [link]. January 31, 2021.

• CG Rappazzo, et. al with J McLellan. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. January 25, 2021.

• S Bhadra, AC Maranhao, I Paik, AD Ellington. A one-enzyme RT-qPCR assay for SARS-CoV-2, and procedures for reagent production. Bio-protocol 11 (2), e3898-e3898202021. January 20, 2021.

• Z Ku, X Xie, E Davidson, X Ye, H Su, VD Menachery, Y Li, Z Yuan, ...JS McLellan, ... Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nature communications 12 (1), 1-13. Janurary 20, 2021.

• X Wang, Z Du, KE Johnson, SJ Fox, M Lachmann, JS McLellan, LA Meyers. The impacts of COVID-19 vaccine timing, number of doses, and risk prioritization on mortality in the US. medRxiv. January 18, 2021.

• JD Gollihar, JS McLellan, DR Boutz, J Goike, A Horton, EC Gardner, F Bartzoka, N Wang, K Javanmardi, A Herbert, S Abbasi, R Renberg, MJ Johanson, JA Cardona, T Segall-Shapiro, L Zhou, RH Nissly, A Gontu, M Byrom, AC Maranhao, AM Battenhouse, V Gejji, L Soto-Sierra, ER Foster, SL Woodard, ZL Nikolov, J Lavinder, WN Voss, A Annapareddy, GC Ippolito, AD Ellington, EM Marcotte, I J Finkelstein, RA Hughes, JM Musser, SV Kuchipudi, V Kapur, G Georgiou, JM Dye. Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality. bioRxiv. January 1, 2021.

• BL Innis, LD Mercer, JA White, R Scharf, R Hjorth, S Lamola, ...JS McLellan, ... Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase … medRxiv. January 1, 2021.

• AR Shiakolas, N Johnson, KJ Kramer, N Suryadevara, D Wrapp, ... JS McLellan, ... Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking. bioRxiv. January 1, 2021.

• P Kaplonek, C Wang, Y Bartsch, S Fischinger, MJ Gorman, K Bowman, ...JS McLellan, ... Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19. bioRxiv. January 1, 2021.

• PS Arunachalam, AC Walls, N Golden, C Atyeo, S Fischinger, C Li, P Aye, ...JS McLellan, ...Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv. January 1, 2021.

• LM Bobay, AC O'Donnell, and H Ochman (2021) Recombination events are concentrated in the spike protein region of Betacoronaviruses. PLoS Genet.  16(12):e1009272. December 17, 2020.

• P Pino, J Kint, D Kiseljak, V Agnolon, G Corradin, AV Kajava, P Rovero, ... JS McLellan, ... Trimeric SARS-CoV-2 spike proteins produced from CHO cells in bioreactors are high-quality antigens. Processes 8 (12), 1539. November 25, 2020.

• R Melero, COS Sorzano, B Foster, JL Vilas, M Martínez, R Marabini, ... JS McLellan, ... Continuous flexibility analysis of SARS-CoV-2 Spike prefusion structures. IUCrJ 7 (6). November 1, 2020.

• A Maranhao, S Bhadra, I Paik, D Walker, AD Ellington. An improved and readily available version of Bst DNA Polymerase for LAMP, and applications to COVID-19 diagnostics. medRxiv. October 5, 2020.

• L Casalino, Z Gaieb, JA Goldsmith, CK Hjorth, AC Dommer, AM Harbison, ... JS McLellan, ... Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein, ACS Central Science 6 (10), 1722-1734. September 23, 2020.

• SW Long, et. al. with J Gollihar, JS. McLellan, C-W Chou, K Javanmardi, IJ. Finkelstein, James M. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. medRxiv. September 22, 2020.

• KB Ragan, S Bhadra, JH Choi, D Towers, CS Sullivan, and AD Ellington. Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation. medRxiv. (Preprint). September 17, 2020.

• E Salazar, et. al. with D Towers, JJ Lavinder, GC Ippolito. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization. The Journal of Clinical Investigation. September 10, 2020.

• KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ... JS McLellan, ... SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586 (7830), 567-571. August 5, 2020.

• W-S Choi, P He, A Pothukuchy, J Gollihar, AD Ellington, W Yang. How a B family DNA polymerase has been evolved to copy RNA. Proceedings of the National Academy of Sciences. August 17, 2020.

• C-l Hsieh, JA Goldsmith, et. al (J Lavinder, G Ipplito, J Maynard, I Finkelstein and J McLellan). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. July 23, 2020.

• BA Purnell, V Gradinaru, M Mbow, B Lell, SP Jochems, B Cisse, S Mboup, ... JS McLellan, ... Modeling coronavirus infection. Science 369 (6504), 640-640. July 8, 2020.

• S Bhadra, AC Maranhao, AD Ellington. A one-enzyme RT-qPCR assay for SARS-CoV-2, and procedures for reagent production. bioRXiv. July 6, 2020.

• CD. Swaim, LA Canadeo, KJ Monte, S Khanna, DJ Lenschow, JM Huibregtse. Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins. Cell Reports. Vol. 31, Iss. 11. June 16, 2020.

• AZ Wec, D Wrapp, et. al., with JS McLellan. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. June 15, 2020. 

• E Salazar, et al. with G Ippolito. Treatment of COVID-19 Patients with Convalescent Plasma. The American Journal of Pathology. (In Press). May 26, 2020.

• S Bhadra, AC Maranhao, AD Ellington. One enzyme reverse transcription qPCR using Taq DNA polymerase. bioRXiv. May 30, 2020.

• Y Watanabe, ZT Berndsen, J Raghwani, GE Seabright, JD Allen, ...  JS McLellan ...Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nature communications 11 (1), 1-10. May 27, 2020.

• T Smith, A Patel, S Ramos, et al. with J McLellan. Immunogenicity of a DNA vaccine candidate for COVID-19. Nature communications 11, 260. May 20, 2020.

• JH Choi, HM Woo, T Lee, S Lee, SM Shim, WJ Park, JS Yang, JA Kim, ... JS McLellan ... Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. PLoS One 15 (5), e0232757. May 8, 2020.

• D Wrapp, D De Vlieger, KS. Corbett, GM Torres, N Wang, W Van Breedam, K Roose, L van Schie, VIB-CMB COVID-19 Response Team, M Hoffmann, S Pöhlmann, BS Graham, N Callewaert, B Schepens, X Saelens, and JS McLellan. Structural Basis for Potent Neutralization of Betacoronaviruses. Cell. May 5, 2020.

• S Bhadra, TE Riedel, S Lakhotia, ND Tran, AD Ellington. High-surety isothermal amplification and detection of SARS-CoV-2, including with crude enzymes. bioRxiv. April 14, 2020.

• S Bhadra, AC Maranhao, and AD Ellington. A one-enzyme RT-qPCR assay for SARS-CoV-2, and procedures for reagent production. bioRxiv. March 31, 2020.

• Y Watanabe, JD Allen, D Wrapp, JS McLellan, M Crispin. Site-specific analysis of the SARS-CoV-2 glycan shield. March 28, 2020.

• D Wrapp, N Wang, KS Corbett, JA Goldsmith, C-Lin Hsieh, O Abiona, BS Graham, JS McLellan. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 1260-1263. March 13, 2020

• TRF Smith, A Patel, S Ramos, D Elwood, X Zhu, J Yan, M Yang, ... JS McLellan,... Rapid development of a synthetic DNA vaccine for COVID-19. Nature Communication 11, Article number: 2601. March 3, 2020.

• AR Shiakolas, KJ Kramer, D Wrapp, SI Richardson, A Schäfer, S Wall, ... JS McLellan,... Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions. bioRxiv. January 1, 2020.

• CG Rappazzo, VT Longping, CI Kaku, D Wrapp, M Sakharkar, D Huang, ... JS McLellan,...  An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19. bioRxiv. January 1, 2020.

• BE Jones, PL Brown-Augsburger, KS Corbett, K Westerndorf, J Davies, ... JS McLellan,... LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv. January 1, 2020.

LCID Affiliiates' Papers
In scientific journals, preprints, etc.

• Howerton E, Contamin L, Mullany LC, Qin M, Reich NG, Bents S, Borchering RK, Jung SM, Loo SL, Smith CP, Levander J, Kerr J, Espino J, van Panhuis WG, Hochheiser H, Galanti M, Yamana T, Pei S, Shaman J, Rainwater-Lovett K, Kinsey M, Tallaksen K, Wilson S, Shin L, Lemaitre JC, Kaminsky J, Hulse JD, Lee EC, McKee CD, Hill A, Karlen D, Chinazzi M, Davis JT, Mu K, Xiong X, Pastore Y Piontti A, Vespignani A, Rosenstrom ET, Ivy JS, Mayorga ME, Swann JL, España G, Cavany S, Moore S, Perkins A, Hladish T, Pillai A, Ben Toh K, Longini I Jr, Chen S, Paul R, Janies D, Thill JC, Bouchnita A, Bi K, Lachmann M, Fox SJ, Meyers LA, Srivastava A, Porebski P, Venkatramanan S, Adiga A, Lewis B, Klahn B, Outten J, Hurt B, Chen J, Mortveit H, Wilson A, Marathe M, Hoops S, Bhattacharya P, Machi D, Cadwell BL, Healy JM, Slayton RB, Johansson MA, Biggerstaff M, Truelove S, Runge MC, Shea K, Viboud C, Lessler J. Evaluation of the US COVID-19 Scenario Modeling Hub for informing pandemic response under uncertainty. Nat Commun. 2023 Nov 20;14(1):7260. PMID: 37985664; PMCID: PMC10661184.

• Jung SM, Loo SL, Howerton E, Contamin L, Smith CP, Carcelén EC, Yan K, Bents SJ, Levander J, Espino J, Lemaitre JC, Sato K, McKee CD, Hill AL, Chinazzi M, Davis JT, Mu K, Vespignani A, Rosenstrom ET, Rodriguez-Cartes SA, Ivy JS, Mayorga ME, Swann JL, España G, Cavany S, Moore SM, Perkins A, Chen S, Paul R, Janies D, Thill JC, Srivastava A, Al Aawar M, Bi K, Bandekar SR, Bouchnita A, Fox SJ, Meyers LA, Porebski P, Venkatramanan S, Adiga A, Hurt B, Klahn B, Outten J, Chen J, Mortveit H, Wilson A, Hoops S, Bhattacharya P, Machi D, Vullikanti A, Lewis B, Marathe M, Hochheiser H, Runge MC, Shea K, Truelove S, Viboud C, Lessler J. Potential impact of annual vaccination with reformulated COVID-19 vaccines: lessons from the U.S. COVID-19 Scenario Modeling Hub. medRxiv [Preprint]. 2023 Nov 18:2023.10.26.23297581. PMID: 37961207; PMCID: PMC10635209.

• Bai Y, Du Z, Wang L, Lau EHY, Fung IC, Holme P, Cowling BJ, Galvani AP, Krug RM, Meyers LA. The public health impact of Paxlovid COVID-19 treatment in the United States. medRxiv [Preprint]. 2023 Sep 7:2023.06.16.23288870. PMID: 37732213; PMCID: PMC10508801.

• Howerton E, Contamin L, Mullany LC, Qin M, Reich NG, Bents S, Borchering RK, Jung SM, Loo SL, Smith CP, Levander J, Kerr J, Espino J, van Panhuis WG, Hochheiser H, Galanti M, Yamana T, Pei S, Shaman J, Rainwater-Lovett K, Kinsey M, Tallaksen K, Wilson S, Shin L, Lemaitre JC, Kaminsky J, Hulse JD, Lee EC, McKee C, Hill A, Karlen D, Chinazzi M, Davis JT, Mu K, Xiong X, Piontti APY, Vespignani A, Rosenstrom ET, Ivy JS, Mayorga ME, Swann JL, España G, Cavany S, Moore S, Perkins A, Hladish T, Pillai A, Toh KB, Longini I Jr, Chen S, Paul R, Janies D, Thill JC, Bouchnita A, Bi K, Lachmann M, Fox S, Meyers LA; UT COVID-19 Modeling Consortium; Srivastava A, Porebski P, Venkatramanan S, Adiga A, Lewis B, Klahn B, Outten J, Hurt B, Chen J, Mortveit H, Wilson A, Marathe M, Hoops S, Bhattacharya P, Machi D, Cadwell BL, Healy JM, Slayton RB, Johansson MA, Biggerstaff M, Truelove S, Runge MC, Shea K, Viboud C, Lessler J. Informing pandemic response in the face of uncertainty: An evaluation of the U.S. COVID-19 Scenario Modeling Hub. medRxiv [Preprint]. 2023 Jul 3:2023.06.28.23291998. Update in: Nat Commun. 2023 Nov 20;14(1):7260. PMID: 37461674; PMCID: PMC10350156.

• Gibson GC, Woody S, James E, Weldon M, Fox SJ, Meyers LA, Bhavnani D. Real time monitoring of COVID-19 intervention effectiveness through contact tracing data. Sci Rep. 2023 Jun 9;13(1):9371. PMID: 37296143; PMCID: PMC10250864.

• Fox SJ, Javan E, Pasco R, Gibson GC, Betke B, Herrera-Diestra JL, Woody S, Pierce K, Johnson KE, Johnson-León M, Lachmann M, Meyers LA. Disproportionate impacts of COVID-19 in a large US city. PLoS Comput Biol. 2023 Jun 1;19(6):e1011149. PMID: 37262052; PMCID: PMC10234557.

• Shea K, Borchering RK, Probert WJM, Howerton E, Bogich TL, Li SL, van Panhuis WG, Viboud C, Aguás R, Belov AA, Bhargava SH, Cavany SM, Chang JC, Chen C, Chen J, Chen S, Chen Y, Childs LM, Chow CC, Crooker I, Del Valle SY, España G, Fairchild G, Gerkin RC, Germann TC, Gu Q, Guan X, Guo L, Hart GR, Hladish TJ, Hupert N, Janies D, Kerr CC, Klein DJ, Klein EY, Lin G, Manore C, Meyers LA, Mittler JE, Mu K, Núñez RC, Oidtman RJ, Pasco R, Pastore Y Piontti A, Paul R, Pearson CAB, Perdomo DR, Perkins TA, Pierce K, Pillai AN, Rael RC, Rosenfeld K, Ross CW, Spencer JA, Stoltzfus AB, Toh KB, Vattikuti S, Vespignani A, Wang L, White LJ, Xu P, Yang Y, Yogurtcu ON, Zhang W, Zhao Y, Zou D, Ferrari MJ, Pannell D, Tildesley MJ, Seifarth J, Johnson E, Biggerstaff M, Johansson MA, Slayton RB, Levander JD, Stazer J, Kerr J, Runge MC. Multiple models for outbreak decision support in the face of uncertainty. Proc Natl Acad Sci U S A. 2023 May 2;120(18):e2207537120. Epub 2023 Apr 25. PMID: 37098064; PMCID: PMC10160947.

• Javan EM, Fox SJ, Meyers LA. Estimating the undetected emergence of COVID-19 in the US. PLoS One. 2023 Apr 6;18(4):e0284025. PMID: 37023065; PMCID: PMC10079060.

• Bi K, Herrera-Diestra JL, Bai Y, Du Z, Wang L, Gibson G, Johnson-Leon M, Fox SJ, Meyers LA. The risk of SARS-CoV-2 Omicron variant emergence in low and middle-income countries (LMICs). Epidemics. 2023 Mar;42:100660. Epub 2022 Dec 7. PMID: 36527867; PMCID: PMC9727964.

• Du Z, Wang L, Shan S, Lam D, Tsang TK, Xiao J, Gao H, Yang B, Ali ST, Pei S, Fung IC, Lau EHY, Liao Q, Wu P, Meyers LA, Leung GM, Cowling BJ. Pandemic fatigue impedes mitigation of COVID-19 in Hong Kong. Proc Natl Acad Sci U S A. 2022 Nov 29;119(48):e2213313119. Epub 2022 Nov 23. PMID: 36417445; PMCID: PMC9860288.

• Wang X, Du Z, James E, Fox SJ, Lachmann M, Meyers LA, Bhavnani D. The effectiveness of COVID-19 testing and contact tracing in a US city. Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2200652119. Epub 2022 Aug 15. PMID: 35969766; PMCID: PMC9407477.

• Bai Y, Du Z, Xu M, Wang L, Wu P, Lau EHY, Cowling BJ, Meyers LA. International risk of SARS-CoV-2 Omicron variant importations originating in South Africa. J Travel Med. 2022 Sep 17;29(6):taac073. PMID: 35704033; PMCID: PMC9278166.

• SJ Fox, K Johnson, B Owirodu, ME Leung, D Walkes, LA Meyers. COVID-19 risk assessment for public events. The University of Texas COVID-19 Modeling Consortium. May 9, 2022.

• M Audirac, M Tec, LA Meyers, S Fox, C Zigler. Impact of the Timing of Stay-at-Home Orders and Mobility Reductions on First-Wave COVID-19 Deaths in US Counties. American Journal of Epidemiology 191 (5), 900-907. May 5, 2022.

• Z Du, Y Bai, L Wang, JL Herrera-Diestra, Z Yuan, R Guo, BJ Cowling, LA Meyers, P Holme. Optimizing COVID-19 surveillance using historical electronic health records of influenza infections. PNAS Nexus. April 14, 2022.

• EY Cramer, EL Ray, VK Lopez, J Bracher, A Brennen, ... LA Meyers... Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the United States. Proceedings of the National Academy of Sciences 119 (15), e2113561119. April 8, 2022.

• Z Du, L Wang, Y Bai, X Wang, A Pandey, MC Fitzpatrick, M Chinazzi, ... LA Meyers. Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study. The Lancet Regional Health-Americas 8, 100182. April 1, 2022.

• Z Du, SJ Fox, T Ingle, MP Pignone, LA Meyers. Projecting the Combined Health Care Burden of Seasonal Influenza and COVID-19 in the 2020–2021 Season. MDM policy & practice 7 (1), 23814683221084631. March 8, 2022.

• SJ Fox, M Lachmann, M Tec, R Pasco, S Woody, Z Du, X Wang, TA Ingle, ... LA Meyers. Real-time pandemic surveillance using hospital admissions and mobility data. Proceedings of the National Academy of Sciences 119 (7), e2111870119. February 1, 2022.

• A Bouchnita, SJ Fox, M Lachmann, GG Herrera-Diestra, LA Meyers. Omicron scenario projections for the Austin-Round Rock MSA. The University of Texas COVID-19 Modeling Consortium. January 25, 2022.

• K Bi, JL Herrera-Diestra, Y Bai, Z Du, L Wang, G Gibson, M Johnson-Leon, ... LA Meyers. The risk of SARS-CoV-2 Omicron variant emergence in low and middle-income countries (LMICs). medRxiv. January 14, 2022.

• A Bouchnita, SJ Fox, JLHDM Lachmann, GG Herrera-Diestra, LA Meyers. COVID-19 Scenario Projections: The Emergence of Omicron in the US-January 2022. The University of Texas COVID-19 Modeling Consortium. January 6, 2022.

• A Bouchnita, SJ Fox, M Lachmann, JL Herrera-Diestra, G Gibson, LA Meyers. COVID-19 Scenario Projections: The Emergence of Omicron in the US.  The University of Texas COVID-19 Modeling Consortium. December 16, 2021.

• S Woody, M Dahan, SJ Fox, K Gaither, M Lachmann, LA Meyers, JG Scott, M Tec, et.al. Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the US. medRxiv December 10, 2021. 

• Y Bai, Z Du, M Xu, L Wang, P Wu, EHY Lau, BJCowling, L Meyers, International risk of SARS-CoV-2 Omicron variant importations originating in South Africa, medRxiv 2021.12.07.21267410, December 7, 2021.

• KE Johnson, S Woody, M Lachmann, SJ Fox, J Klima, TS Hines, LA Meyers. Real-Time Projections of SARS-CoV-2 B.1.1.7 Variant in a University Setting, Texas, USA. Emerging Infectious Diseases. 27(12):3188-3190. December 2021. 

• N Arslan, DP Morton, J Pichette, D Walkes, and LA Meyers. Projections for Austin’s COVID-19 Staged Alert System, Incorporating Reported Cases as Additional Indicator. The University of Texas COVID-19 Modeling Consortium. November 17, 2021. 

• SM Moghadas, P Sah, A Shoukat, LA Meyers, AP Galvani. Population Immunity Against COVID-19 in the United States. Annals of Internal Medicine.  November 2021.

• N Arslan, DP Morton, D Walkes, and LA Meyers.  Projections for Variants of Concern under Austin’s COVID-19 Staged-Alert System.  The University of Texas COVID-19 Modeling Consortium. October 20, 2021.

• Y Ding, SK Agrawal, J Cao, LA Meyers, JJ Hasenbein. Surveillance testing for rapid detection of outbreaks in facilities. arXiv preprint arXiv:2110.00170, October 1, 2021.

• M Audirac, M Tec, LA Meyers, SJ Fox, C Zigler. How Timing of Stay-at-home Orders and Mobility Reductions Impacted First-Wave COVID-19 Deaths in US Counties, medRxiv. September 26, 2021.

• R Pasco, M Lachmann, SJ Fox, LA Meyers. Mitigating COVID-19 in schools with facemasks and proactive testing.  The University of Texas COVID-19 Modeling Consortium. September 14, 2021.

• SM Moghadas, P Sah, A Shoukat, LA Meyers, Population Immunity Against COVID-19 in the United States, Annals of Internal Medicine, September 14, 2021.

• KE Johnson, R Pasco, S Woody, M Lachmann, D Bhavnani, J Klima, SJ Fox, LA Meyers. COVID-19 projections for the reopening of the University of Texas at Austin in fall 2021. The University of Texas COVID-19 Modeling Consortium. August 11, 2021.

• R Capobianco, V Kompella, J Ault, G Sharon, S Jong, S Fox, LA Meyers, P Wurman, P Stone. Agent-based markov modeling for improved COVID-19 mitigation policies Journal of Artificial Intelligence Research 71, 953-992, August 18, 2021.

• SJ Fox, M Lachmann, A Bouchnita, S Woody, R Pasco, M Johnson-Leon, T Ingle, K Johnson, LA Meyers. COVID-19 scenario projections for Austin, Texas - August 2021 . The University of Texas COVID-19 Modeling Consortium. August 06, 2021.

• M Lachmann, A Bouchnita, S Woody, R Pasco, M Johnson-Leon, K Johnson, SJ Fox, LA Meyers. COVID-19 scenario projections for Austin, Texas –– July 2021. The University of Texas COVID-19 Modeling Consortium. July 19, 2021.

• Z Du, L Wang,Y Bai, X Wang, A Pandey, M Chinazzi, A Pastore y Piontti, N Hupert, M Lachmann, A Vespignani, AP Galvani, BJ Cowling, LA Meyers. Cost Effective Proactive Testing Strategies During COVID-19 Mass Vaccination: A Modelling Study. The Lancet. July 1, 2021.

• X Wang, Z Du, K Johnson, R Pasco, SJ Fox, M Lachmann, JS McLellan, LA Meyers. Effects of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, Emerging Infectious Disease Volume 27, Number 7—July 2021.

• H Yang, O Sürer, D Duque, D Morton, B Singh, SJ Fox, R Pasco, K Pierce, P Rathouz, V Valencia, Z Du, M Pignone, M Escott, SI Adler, SC Johnston, LA Meyers. Design of COVID-19 staged alert systems to ensure healthcare capacity with minimal closures. Nature Communications, June 18, 2021.

• Z Du, L Wang, S Shan, D Lam, TK Tsang, J Xiao, H Gao, B Yang, ST Ali, S Pei, IC-H Fung, EHY Lau, Q Liao, P Wu, LA Meyers, GM Leung, BJ Cowling. Pandemic fatigue impedes mitigation of COVID-19 in Hong Kong. Research Square, June 10, 2021. 

• D Gillespie, LA Meyers, M Lachmann, SC Redd, JM Zenilman, The Experience of 2 Independent Schools With In-Person Learning During the COVID-19 Pandemic. Journal of School Health. May 2021.

• TA Ingle, M Morrison, X Wang, T Mercer, V Karman, S Fox, LA Meyers. Projecting COVID-19 isolation bed requirements for people experiencing homelessness. Plos One. May 12, 2021. 

• N Arslan, O Sürer, DP Morton, H Yang, M Lachmann, S Woody, SJ Fox, and LA Meyers. COVID-19 alert stages, healthcare projections and mortality patterns in Austin, Texas, May 2021.  The University of Texas COVID-19 Modeling Consortium. May 5, 2021.

• Z Du, L Wang, B Yang, ST Ali, TK Tsang, S Shan, P Wu, EHY Lau, BJ Cowling, and LA Meyers. Risk for international importations of variant SARS-CoV-2 originating in the United Kingdom. Emerging infectious diseases 27, no. 5. May 5, 2021.

• KE Johnson, M Lachmann, M Stoddard, R Pasco, SJ Fox, LA Meyers, A Chakravarty. Detecting in-school transmission of SARS-COV-2 from case ratios and documented clusters. medRxiv. April 28, 2021.

• P Rathouz, V Valencia, P Chang, D Morton, H Yang, O Surer, S Fox, LA Meyers, E Matsui, A Haynes. Survival analysis methods for analysis of hospitalization data: Application to COVID-19 patient hospitalization experience. medRxiv 2021.04.14.21255511. April 20, 2021.

• S Woody, E Javan, K Johnson, R Pasco, M Johnson León, M Lachmann, SJ Fox, and LA Meyers. Spatial distribution of COVID-19 infections and vaccinations in Austin, Texas. The University of Texas COVID-19 Modeling Consortium. April 12, 2021. 

• Z Du, L Wang, B Yang, ST Ali, TK Tsang, S Shan, P Wu, E Lau, BJ Cowling, LA Meyers. International risk of the new variant COVID-19 importations originating in the United Kingdom. medRxiv 2021.01.09.21249384. March 15, 2021.

• Kaitlyn E. Johnson, Spencer Woody, Michael Lachmann, Spencer J. Fox, Jessica Klima, Terrance S. Hines, Lauren Ancel Meyers. Early estimates of SARS-CoV-2 B.1.1.7 variant emergence in a university setting. medRxiv. March 9, 2021.

• S Stockmaier, N Stroeymeyt, EC Shattuck, DM Hawley, LA Meyers, and DI Bolnick. Infectious diseases and social distancing in nature. Science. 371, no. 6533. March 5, 2021.

• KE Johnson, S Woody, R Pasco, C Matsui, M Lachmann, SJ Fox, LAl Meyers. Emergence of the B.1.1.7 SARS-CoV-2 variant at the University of Texas at Austin . The University of Texas COVID-19 Modeling Consortium. March 5, 2021.

• M Lachmann, SJ Fox, S Woody, KE Johnson, LA Meyers. Potential impacts of statewide relaxation of COVID-19 policies, the B.1.1.7 variant, and the vaccination in Austin . The University of Texas COVID-19 Modeling Consortium. March, 2021.

• KE Johnson, S Woody, R Pasco, C Matsui, M Lachmann, SJ Fox, LA Meyers. Early introductions and projections of the B.1.1.7 SARS-CoV-2 variant at the University of Texas at Austin. The University of Texas COVID-19 Modeling Consortium. February 12, 2021.

• KE Johnson, S Woody, M Lachmann, SJ Fox, J Klima, TS Hines, LA Meyers. Supplementary Material to “Early estimates of SARS-CoV-2 B.1.1.7 variant emergence in a university setting". February 12, 2021.

• Z Du, A Pandey, Y Bai, MC Fitzpatrick, M Chinazzi, AP y Piontti, M Lachmann, A Vespignani, BJ Cowling, AP Galvani, and LA Meyers, 2021. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. The Lancet Public Health, 6(3), pp.e184-e191. February 4, 2021.

• KA Pierce, E Ho, X Wang, R Pasco, Z Du, G Zynda, J Song, G Wells, SJ Fox, and LA Meyers. Early COVID-19 pandemic modeling: Three compartmental model cases studies from Texas, USA. Computing in Science & Engineering. February 1, 2021.

• SM Moghadas, TN Vilches, K Zhang, CR Wells, A Shoukat, BH Singer, LA Meyers, KM Neuzil, JM Langley, MC Fitzpatrick, AP Galvani. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States, Clinical Infectious Diseases, 2021;,ciab079. January 30, 2021.

• C Matsui, KE Johnson, R Pasco, M Lachmann, SJ Fox, LAl Meyers. COVID-19 Campus Introduction Risks for Spring 2021 at the University of Texas at Austin. The University of Texas COVID-19 Modeling Consortium. January 29, 2021.

• E Javan, E Kushnereit, B Betke, S Woody, R Pasco, K Pierce, K Johnson, M Johnson-León, M Lachmann, SJ Fox, LA Meyers. Heterogeneous burden of the COVID-19 pandemic in Central Texas. The University of Texas COVID-19 Modeling Consortium. January 27, 2021.

• S Risanger, B Singh, D Morton, and LA Meyers. Selecting pharmacies for COVID-19 testing to ensure access. Health Care Management Science, 1-9. January 10, 2021.

• SM Moghadas, TN Vilches, K Zhang, CR Wells, A Shoukat, BH Singer, LA Meyers, KM Neuzil, JM Langley, MC Fitzpatrick and AP Galvani. The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv : the preprint server for health sciences, 2020.11.27.20240051. January 2, 2021.

• H Yang, M Lachmann, Ö Sürer, SJ Fox, DP Morton, LA Meyers. Projecting Need for a COVID-19 Alternate Care Site (ACS) in Austin. The University of Texas COVID-19 Modeling Consortium. January 8, 2021.

• H Yang, Ö Sürer, D Duque, DP Morton, B Singh, SJ Fox, R Pasco, K Pierce, P Rathouz, Z Du, M Pignone, ME Escott, SI Adler, SC Johnston, LA Meyers. Design of COVID-19 Staged Alert Systems to Ensure Healthcare Capacity with Minimal Closures.  medRxiv. December 24, 2020.

• M Lachmann, S Fox, and LA Meyers. Potential Impact of Holiday Gatherings on COVID-19 Hospitalizations in Austin. The University of Texas COVID-19 Modeling Consortium. December 23, 2020.

• Z Du, SJ Fox, T Ingle, MP Pignone, and LA Meyers. Projecting the combined healthcare burden of seasonal influenza and COVID-19. medRxiv. December 22, 2020.

• SJ Fox, P Potu, Mi Lachmann, R Srinivasan, LA Meyers. The COVID-19 herd immunity threshold is not low: A re-analysis of European data from spring of 2020. medRxiv, December 3, 2020.

• EM Javan, SJ Fox, LA Meyers. Estimating the unseen emergence of COVID-19 in the US. medRxiv, November 13, 2020. 

• S Bismark, S Risanger, D Morton, M Pignone and LA Meyers. Expanding Access to COVID-19 Tests through US Postal Service Facilities. Medical Decision Making. October 30, 2020.

• RF Pasco, SJ Fox, SC Johnston, M Pignone, LA Meyers. Estimated Association of Construction Work With Risks of COVID-19 Infection and Hospitalization in Texas. JAMA Netw Open. 2020;3(10):e2026373. October 29, 2020.

• M Lachmann, SJ Fox, M Tec, R Pasco, Z Du, S Woody, M Dahan, K Gaither, K Pierce, J Scott, G Wells, LA Meyers. Texas Trauma Service Area (TSA) COVID-19 transmission estimates and healthcare projections - Updated Oct. 20, 2020. The University of Texas COVID-19 Modeling Consortium. October 20, 2020.

• X Wang, RF Pasco, Z Du, M Petty, SJ Fox, AP Galvani, et al. Impact of social distancing measures on coronavirus disease healthcare demand, central Texas, USA. Emerg Infect Dis. October 2020.

• C Matsui, R Pasco, K Johnson, SJ Fox, LA Meyers. COVID-19 Transmission Risks for Reopening The University of Texas at Austin. The University of Texas COVID-19 Modeling Consortium. September 25, 2020.

• X Wang, Z Du, G Huang, RF Pasco, SJ Fox, AP Galvani, M Pignone, SC Johnston, and LA Meyers. Effects of Cocooning on Coronavirus Disease Rates after Relaxing Social Distancing. Emerging Infectious Diseases. September 21, 2020.

• S Risanger, B Singh, D Morton, LA Meyers. Selecting Pharmacies for COVID-19 Testing to Ensure Access. medRxiv. September 18, 2020. 

• Kelly Pierce, Michael Lachmann, Spencer J. Fox, Remy Pasco, Lauren Ancel Meyers Houston Area COVID-19 School Introduction Risks.  The University of Texas COVID-19 Modeling Consortium. August 28, 2020.

• C Matsui, K Johnson, R Pasco, M Lachmann, SJ Fox, LA Meyers. COVID-19 Campus Introduction and Gathering Risks for Reopening the University of Texas at Austin. The University of Texas COVID-19 Modeling Consortium. August 20, 2020.

• M Lachmann, SJ Fox, M Tec, R Pasco, M Johnson, J Lu, Z Du, S Woody, J Starling, M Dahan, K Gaither, K Pierce, J Scott, G Wells, LA Meyers. Texas Trauma Service Area (TSA) COVID-19 transmission estimates and healthcare projections: August 25, 2020. The University of Texas COVID-19 Modeling Consortium. Updated after a presentation on August 19, 2020.

• Z Du, E Javan, C Nugent, BJ Cowling, LA Meyers. Using the COVID-19 to influenza ratio to estimate early pandemic spread in Wuhan, China and Seattle, US. eClinicalMedicine. August 12, 2020.

• M Lachmann, SJ Fox, M Tec, R Pasco, M Johnson, J Lu, Z Du, S Woody, J Starling, M Dahan, K Gaither, K Pierce, J Scott, G Wells, LA Meyers. Texas Trauma Service Area (TSA) COVID-19 transmission estimates and healthcare projections: August 1, 2020. The University of Texas COVID-19 Modeling Consortium. August 1, 2020.

• SJ Fox, M Lachmann, LA Meyers. Risks of COVID-19 Introductions as Schools Reopen. The University of Texas COVID-19 Modeling Consortium. Presented to The New York Times July 31, 2020.

• D Duque, DP Morton, B Singh, Z Du, R Pasco, LA Meyers. Timing social distancing to avert unmanageable COVID-19 hospital surges. Proceedings of the National Academy of Sciences. July 29, 2020. 

• SJ Fox, M Lachmann, LA Meyers. COVID-19 Campus Introduction Risks for School Reopenings. The University of Texas COVID-19 Modeling Consortium. July 22, 2020.

• M Tec, M Lachmann, SJ Fox, R Pasco, S Woody, J Starling, M Dahan, K Gaither, J Scott, LA Meyers. Austin COVID-19 transmission estimates and healthcare projections. The University of Texas COVID-19 Modeling Consortium. July 15, 2020. 

• Scarpino SV, Scott JG, Eggo RM, Clements B, Dimitrov NB, Meyers LA. Socioeconomic bias in influenza surveillance. PLoS Comput Biol 16(7): e1007941. July 9, 2020.

• SJ Fox, R Pasco, M Tec, Z Du, M Lachmann, J Scott, LA Meyers. The impact of asymptomatic COVID-19 infections on future pandemic waves. medRxiv. June 22, 2020.

• H Yang, D Duque, Ö Sürer, DP Morton, R Pasco, K Pierce, SJ Fox, LA Meyers. Staged Strategy to Avoid Hospital Surge and Preventable Mortality, while Reducing the Economic Burden of Social Distancing Measures. The University of Texas COVID-19 Modeling Consortium.  June 15, 2020.

• Z Du, X Xu, L Wang, SJ Fox, BJ Cowling, AP Galvani, LA Meyers. Effects of proactive social distancing on COVID-19 outbreaks in 58 cities, China. Emerg Infect Dis. June 9, 2020.

• LA Meyers, Z Du, RM Krug. Hoping for a COVID-19 antiviral that limits virus spread. Nature Microbiology. June 2, 2020.

• Z Du, C Nugent, AP Galvani, RM Krug & LA Meyers. Modeling mitigation of influenza epidemics by baloxavir. Nature Communications. June 2, 2020.

• Z Du, X Xu, Y Wu, L Wang, BJ Cowling, and LA Meyers. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerging Infectious Diseases. June 2020.

• Z Du, L Wang, S Chauchemez, X Xu, X Wang, BJ Cowling, and LA Meyers. Risk for transportation of 2019 novel coronavirus disease from Wuhan to other cities in China. Emerg Infect Diseases. May 2020.

• D Duque, M Tec, DP Morton, J Scott, H Yang, R Pasco, K Pierce, SJ Fox, M Pignone, P Hudson, and LA Meyers. Staged Strategy to Avoid Hospital Surge and Preventable Mortality, while Reducing the Economic Burden of Social Distancing Measures. The University of Texas COVID-19 Modeling Consortium. Presented to the city of Austin and Travis County on May 18, 2020.

• D Duque, DP Morton, B Singh, Z Du, R Pasco, LA Meyers, COVID-19: How to Relax Social Distancing If You Must. medRxiv. May 5, 2020.

• Z Du, X Xu, L Wang, SJ Fox, BJ Cowling, AP Galvani & LA Meyers. Proactive social distancing mitigates COVID-19 outbreaks within a month across 58 mainland China cities. Emerging Infectious Disease. April 29, 2020.

• K Pierce, E Ho, X Wang, R Pasco, Z Du, S Fox, G Zynda, J Song, LA Meyers. COVID-19 Healthcare Demand Projections: Beaumont-Port Arthur MSA, Texas. The University of Texas COVID-19 Modeling Consortium. April 29, 2020.

• K Pierce, E Ho, X Wang, R Pasco, Z Du, S Fox, G Zynda, J Song, LA Meyers. COVID-19 Healthcare Demand Projections: Houston-The Woodlands-Sugar Land MSA, Texas. The University of Texas COVID-19 Modeling Consortium. April 28, 2020.

• D Duque, DP Morton, B Singh, Z Du, R Pasco, LA Meyers. COVID-19 in Austin, Texas: Averting healthcare surges while relaxing social distancing. The University of Texas COVID-19 Modeling Consortium. April 28, 2020.

• Z Du, X Xu, Y Wu, L Wang, BJ Cowling and LA Meyers. COVID-19 serial interval estimates based on confirmed cases in public reports from 86 Chinese cities. medRxiv. April 27, 2020.

• X Wang, Z Du, G Huang, S Fox, LA Meyers. COVID-19 in Austin, Texas: Relaxing Social Distancing Measures. The University of Texas COVID-19 Modeling Consortium. April 23, 2020.

• X Wang, RF Pasco, Z Du, M Petty, SJ Fox, AP Galvani, M Pignone, SC Johnston, LA Meyers. Impact of Social Distancing Measures on COVID-19 Healthcare Demand in Central Texas. medRxiv. April 22, 2020.

• X Wang, R Pasco, K Pierce, Z Du, S Fox, LA Meyers. COVID-19 Healthcare Demand Projections: Austin, Texas: April 20, 2020. The University of Texas COVID-19 Modeling Consortium. April 21, 2020. 

• E Javan, SJ Fox, LA Meyers. The unseen and pervasive threat of COVID-19 throughout the US. medRxiv. April 18, 2020.

• R Pasco, X Wang, Z Du, SJ Fox, LA Meyers. COVID-19 in Austin, Texas: Epidemiological Assessment of Grocery Shopping. The University of Texas COVID-19 Modeling Consortium. April 17, 2020. 

• S Woody, M Tec, M Dahan, K Gaither, M Lachmann, SJ Fox, LA Meyers, and J Scott. Projections for first-wave COVID-19 deaths across the U.S. using social-distancing measures derived from mobile phones. The University of Texas COVID-19 Modeling Consortium. April 17, 2020. 

• X Wang, Z Du, R Pasco, K Pierce, M Petty, SJ Fox, M Pignone, C Johnston, LA Meyers.  COVID-19 Healthcare Demand Projections: Austin, Texas: April 6, 2020. The University of Texas COVID-19 Modeling Consortium. April 6, 2020.

• R Pasco, Z Du, X Wang, M Petty, SJ Fox, LA Meyers. COVID-19 in Austin, Texas: Epidemiological Assessment of Construction Work. The University of Texas COVID-19 Modeling Consortium. April 5, 2020. 

• E Javan, SJ Fox, LA Meyers. Probability of current COVID-19 outbreaks in all US counties. The University of Texas COVID-19 Modeling Consortium. April 3, 2020.

• Z Du, X Wang, R Pasco, M Petty, SJ Fox, and LA Meyers. COVID-19 Healthcare Demand Projections: 22 Texas Cities. The University of Texas COVID-19 Modeling Consortium. April 5, 2020.

• SM Moghadas, A Shoukat, MC Fitzpatrick, CR Wells, P Sah, A Pandey, JD Sachs, Z Wang, LA Meyers, BH Singer, AP Galvani. Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proceedings of the National Academy of Sciences. April 3, 2020.

• CR Wells, P Sah, SM Moghadas, A Pandey, A Shoukat, Y Wang, Z Wang, LA Meyers, BH Singer, AP Galvani. Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proceedings of the National Academy of Sciences. 117(13):7504-9. March 31, 2020.

• Z Du, C Nugent, BJ Cowling, LA Meyers. Hundreds of severe pediatric COVID-19 infections in Wuhan prior to the lockdown. medRxiv. March 27, 2020.

• R Pasco, X Wang, M Petty, Z Du, SJ Fox, M Pignone, C Johnston, and LA Meyers. COVID-19 Healthcare Demand Projections: Austin, Texas: March, 2020. The University of Texas COVID-19 Modeling Consortium. March 26, 2020. 

• CO Buckee, et. al., with LA Meyers. Aggregated mobility data could help fight COVID-19. Science. March 23, 2020. 

• LA Meyers. The secret life of coronavirus: Why we need such drastic social distancing measures. The Economist Intelligence Unit. March 20, 2020.

• Z Du, X Xu, Y Wu, L Wang, BJ Cowling and LA Meyers. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerging Infectious Diseases. March 19, 2020. 

• M Morrison, LA Castro and LA Meyers. Conscientious vaccination exemptions in kindergarten to eighth-grade children across Texas schools from 2012 to 2018: A regression analysis. PLoS medicine 17, no. 3. March 10, 2020.